Sign Out
KISUNLA is indicated for the treatment of patients with Mild Cognitive Impairment (MCI) due to Alzheimer's disease and Mild Alzheimer's dementia (Early Symptomatic Alzheimer's disease) that are apolipoprotein E ε4 (ApoE ε4) heterozygotes or non-carriers.
Beta amyloid evidence consistent with Alzheimer's disease (AD) should be confirmed using a validated test prior to initiating treatment.
Continue with Google